All In Biotech

Drug Trial Radar · NCT06536036

Evaluate the Effects of Food on the Pharmacokinetics of SIM0270

A Single Center, Randomized, Open Label, Single Dose, Two-Period, Crossover Phase I Study to Evaluate the Effect of Food (high-fat/standard Meal) on the Pharmacokinetics of SIM0270 in Healthy Adult Subjects in China

Last checked: Nov 19, 2026Latest source record: Dec 2, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

16

Actual

Start

Jul 23, 2024

Primary completion

Oct 16, 2024

Study completion Oct 16, 2024

Sponsor

Sponsor type
Industry
Collaborators
Nanjing Zaiming Pharmaceutical Co., Ltd.
First posted
Aug 2, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a randomized, open label, single dose, two-period, crossover trial phase I study. The purpose of this study is to evaluate the food effect on the pharmacokinetics(PK) of SIM0270 after oral administration under fasted, standard meal, or high-fat diet conditions.

Conditions

  • Healthy Participants

Interventions

  • SIM0270Drug

    Use according to the prescribed protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PK parameters: Peak Plasma Concentration (Cmax)Time frame: Day1 to Day 37
  2. PK parameters:Area under the plasma concentration versus time curve (AUC)Time frame: Day1 to Day 37
  3. PK parameters: Half-life (t1/2)Time frame: Day1 to Day 37

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Shandong First Medical University

    Jinan, Shandong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.